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CYTOMEGALOVIRUS (CMV) INFECTION IN ALLOGENEIC NON-MYELOA-
BLATIVE STEM CELL TRANSPLANTATION RECIPIENTS
Chandrasekar, P.1, King, R.2, Dansey, R.2, Akhtar, A.2, Mellon-Rep-
pen, S.2, Alangaden, G.1 1. Infectious Disease Division, Detroit, MI; 2.
Bone Marrow Transplant, Detroit, MI.
Background: Non-myeloablative technique of allogeneic stem
cell transplantation is recent and increasingly popular; data regard-
ing CMV infection are limited in such transplant recipients. Meth-
ods: We examined our data on patients undergoing non-myeloa-
blative transplantation (NMT) during Sept 2000-Dec 2002.
Results: Thirty-one patients (men 16, mean age 54; women 15,
mean age 47) underwent non-myeloablative transplantation
(NMT) during Sept 2000-Dec 2002 (Number of patients: 3-2000;
16-2001; 12-2002). Major underlying diseases were renal cell car-
cinoma (11), myeloma (5), Non-Hodgkin’s lymphoma (5) and
breast cancer (3). Of 31 patients, 10 received matched unrelated
donor stem cells. Preparative regimens were Fludarabine with
cyclophosphamide (19 patients) or ﬂudarabine with total body
irradiation (12 patients). Most (29/31) received peripheral blood
stem cells. Mean duration of neutropenia was 6.6 days (range 0-16).
Fifteen of 31 patients were CMV seropositive. None received
prophylaxis against CMV; CMV antigen (pp65) test was routinely
done once weekly. CMV antigenemia occurred in 12 patients (with
viremia in 3), 9 of whom were seropositive and 3 seronegative, after
a mean duration of 56 days (range 24-165) from transplant. Anti-
genemia after 100 days occurred in only 1 patient. Four of 12
patients with antigenemia had received stem cells form unrelated
donors. None developed CMV disease. Of the total 31 patients
transplanted, 19 died. CMV antigenemia was of low level in most
patients with prompt response to IV ganciclovir. Conclusions:
Our preliminary data demonstrate that CMV infection is common
in NMT recipients; routine surveillance and pre-emptive therapy
with ganciclovir are effective in preventing CMV disease.
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ANTI-DONOR ISOAGGLUTININ REDUCTION AND PURE RED CELL APLA-
SIA AFTER MAJOR ABO-INCOMPATIBLE HSCT
Stussi, G.1, Bucheli, E.1, Passweg, J.R.2, Halter, J.1, Schanz, U.1,
Gmuer, J.1, Gratwoh, L.A.2, Seebach, J.D.1 1. University Hospital,
Zurich, Switzerland; 2. University Hospital, Basel, Switzerland.
Posttransplant pure red cell aplasia (PRCA) occurs after major or
bidirectional ABO-incompatible HSCT and presumably is caused
by the persistence or a secondary rise of anti-donor host B cells.
However, it is not known, whether the incidence of PRCA depends
on the level and/or reduction of anti-donor isoagglutinins prior to
HSCT. We performed a retrospective two-center analysis of 153
consecutive patients receiving major (n  123) or bidirectional
(n  46) ABO incompatible, allogeneic HSCT between 1980 and
2002. Posttransplant PRCA was deﬁned as reticulocyte count of
less than 1% for more than 100 days along and a lack of RBC
precursors in a bone marrow specimen. In one center, isoaggluti-
nins of the recipient were removed by plasma exchange and/or
in-vivo absorption (IVA) with pretransplant transfusion of donor-
type RBC. Consequently, these patients received exclusively do-
nor-type RBC after HSCT. The other center depleted donor stem
cells from RBC and transfused recipient- or O-type RBC as long as
anti-donor isoagglutinins were present. Overall, 12 patients devel-
oped PRCA after HSCT (12/153, 7.8%). All received HSCT from
a major ABO-incompatible donor. The mean RBC take was de-
layed to 224 d in patients with PRCA (range 143-382 d) compared
to 24 d and the requirement for RBC transfusions was increased
(36 vs. 12, p  0.001). RBC engraftment was associated with a
simultaneous decrease of anti-donor isoagglutinins (11/12). Re-
markably, 9/12 patients with PRCA were transplanted in the center
where isoagglutinin titers were not reduced prior to HSCT. In this
center, 9/46 patients (20%) developed PRCA, whereas only 3 cases
occurred in the other center (3/107, 3%, p  0.001). Patients with
PRCA had higher pretransplant isoagglutinin titers (median 1:64
vs. 1:16, p  0.001). Pretransplant IVA resulted in hemolysis, but
had no serious side effects. The time to RBC engraftment was also
delayed after exclusion of patients with PRCA indicating a general
negative effect of anti-donor isoagglutinins on erythropoiesis (p 
0.005). Beside pretransplant IVA, peripheral stem cell source was
the only signiﬁcant variable in multivariate analysis positively as-
sociated with RBC engraftment. In summary, PRCA after HSCT
depends on the levels and/or reduction of pretransplant anti-donor
isoagglutinins. IVA of these antibodies by transfusions of incom-
patible RBC seems to be a feasible, safe, and cost-effective method
to prevent the occurrence of PRCA.
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PARTIAL T CELL DEPLETION FOR UNRELATED DONOR BMT FOR CHIL-
DREN WITH SEVERE APLASTIC ANEMIA (SAA): ENGRAFTMENT WITH
MINIMAL GVHD
Bunin, N., Leahey, A., Grupp, S., Pierson, G., Monos, D. Children’s
Hospital of Philadelphia, Philadelphia, PA.
Unrelated donor BMT for SAA is reserved for patients who lack
an HLA identical sibling, and fail medical therapy. However,
increased graft rejection is a potential problem in these heavily
transfused patients (pts), and the risk of severe GVHD is also
increased with unrelated donors. Improved techniques in HLA
typing to ensure molecular matching may decrease the risk of
GVHD, but may limit donor availability. Partial T cell depletion
may decrease the risk of severe GVHD, while still maintaining
sufﬁcient donor T lymphocytes to ensure engraftment. We report
on 12 patients with SAA who underwent unrelated donor BMT.
Pts had failed medical therapy with ATG, steroids and cyclospor-
ine (CSA) (9) or relapsed following initial responses (3). Median
age was 6 yrs (1-20), and there were 5 males, 7 females. Median
time from diagnosis of SAA to BMT was 466 days(155-1084).
Donors were serology class I (A, B) and DRB1 matched for 4 pts,
mismatched at the A locus for 3 pts, at B locus for 3 pts, and at DR
for 2 pts. Conditioning included Ara-C 12 g/m2, cyclophospha-
mide (CPM) 90 mg/kg and total body irradiation 12-13.2 Gy for 4
pts, and thiotepa 10 mg/kg, CPM 120 mg/kg and TBI 12 Gy for 8
pts. The last 7 pts received ALG 1.5 mg/kg for 3 days prior to
marrow infusion. In vitro partial T cell depletion was T10B9 and
complement (8 pts) or OKT3 and complement (4 pts). Cyclospor-
ine was used for 3 months post BMT and then tapered. Median
nucleated cell dose post T depletion was 0.8 x 108/kg (0.24-3.2),
and median CD3 cell dose was 1 x 106/kg (0.2-9.2). All patients
engrafted, with a median time of 18 days to ANC  500 (14-34),
and all but one pt became platelet transfusion independent. Acute
GVHD grades I-II developed in 4 pts; two developed limited
cGVHD. Nine pts (75%) are alive 3-147 mos post BMT and
transfusion independent. Morbidity included intractable VOD in a
pt with Schwachman-Diamond syndrome, who underwent suc-
cessful related donor live transplant. Three pts died at d 165, 237
and 282 from resistant CMV, renal failure, and PCP respectively.
This series suggests that an aggressive immunosuppressive condi-
tioning regimen with partial T cell depletion results in successful
engraftment and minimal GVHD in pediatric patients with SAA,
even with HLA mismatched donors.
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ANTI-THYMOCYTE-GLOBULIN (ATG) IN THE NONMYELOABLATIVE
CONDITIONING FOR CANINE HEMATOPOIETIC CELL TRANSPLANT
(HCT)
Diaconescu, R.1, Little, M.-T.1, Leisenring, W.1,2, Yunusov, M.1,
Hogan, W.1, Sorror, M.1, Baron, F.1, Storb, R.1,2 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. University of Washington,
Seattle, WA.
We tested whether pretransplant immunosuppression with ca-
nine-speciﬁc rabbit ATG (SangStat), combined with 1 Gy total
body irradiation (TBI) and posttransplant mycophenolate mofetil/
cyclosporine (MMF/CSP) would assure stable engraftment in our
canine HCT model. First, pharmacokinetic studies were done in 4
dogs, with cumulative ATG doses of 2–5 mg/kg, subcutaneously.
ATG was most effective in depleting peripheral T cells (CD4
and CD8), intermediate on B cells and did not deplete other
blood cells. Lymph node biopsies taken after 2 mg/kg ATG
showed 50% T-cell depletion. Serum levels of ATG peaked at
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6–42 g/ml (days 4–6), in synchrony with the T-cell nadirs, and
became undetectable by day 13. Antibodies to rabbit ATG ap-
peared after 6–7 days, and their titers increased as ATG was
cleared from the circulation. We then evaluated the immunosup-
pressive effects of ATG using allogeneic skin grafts. Median skin
graft survival in 5 dogs given ATG was 14 days, compared to 8 days
among 28 controls (p  0.0003). Based on these observations, an
HCT protocol was designed; 5 dogs were given ATG (3.5–5
mg/kg) between days –12 and –7 to target a 90–95% depletion of
circulating T cells. ATG levels were undetectable by day 0, ex-
cluding possible effects on donor T cells. On day 0, dogs were
given 1 Gy TBI and marrow from dog leukocyte antigen-identical
donors. Median cell doses infused (millions/kg) were: total nucle-
ated cells (TNC)  263; CD34  6.6 and CD3  18. Posttrans-
plant immunosuppression was MMF/CSP for 4 and 5 weeks,
respectively. All recipients showed initial donor chimerism, with
maximal values ranging from 10–75% (median 25%) for granulo-
cytes and 5–40% (median 25%) for mononuclear cells. Four dogs
rejected their grafts after a median of 9.5 weeks (range 8–18
weeks), without cytopenias, and they reverted to autologous hema-
topoiesis. The 5th dog has remained a long-term mixed chimera
(36 weeks). The median times to rejection were 11 weeks (pro-
jected) in the study group and 10 weeks in the control group, not
given ATG (p  0.20, log-rank test). Analysis of the impact of cell
doses suggested that TNC had the highest Spearman correlation
coefﬁcient with the duration of donor chimerism, 0.82 (p  0.09).
We conclude that ATG reliably depleted circulating T cells by
90–95% and lymph node T cells by approximately 50%. Even so,
administering ATG before an otherwise inadequate conditioning
dose of 1 Gy TBI failed to lead to uniform stable hematopoietic
engraftment.
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THE IMPACT OF PRE-TRANSPLANT ANEMIA ON LONG-TERM SURVIVAL
FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION
Xenocostas, A.1, Wong, C.J.2, Lazongas, C.3, Sutton, D.M.3, Daly, A.3,
Kiss, T.L.4, Lipton, J.H.3, Messner, H.A.3 1. Department of Hema-
tology, London Health Sciences Centre and the University of West-
ern Ontario, London, ON, Canada; 2. Robarts Clinical Trials, Robarts
Research Institute and the University of Western Ontario, London,
ON, Canada; 3. Department of Medical Oncology and Hematology,
Princess Margaret Hospital/University Health Network and the Uni-
versity of Toronto, Toronto, ON, Canada; 4. Department of Hemato-
Oncology, Sacre Coeur Hospital/University of Montreal, Montreal, QC,
Canada.
Background: Anemia is a common ﬁnding in patients with
malignancies and is associated with reduced survival times. The
impact of anemia on survival during allogeneic bone marrow trans-
plantation (alloBMT) was not known. Recently, we identiﬁed that
low pre-transplant hemoglobin (PT-Hb) levels were associated
with increased mortality during the ﬁrst 6 months after BMT.
However, the impact of the PT-Hb on long-term survival was not
known. Study Design and Methods: Data from 519 consecutive
patients receiving transplants between January 1995 and March
2000 were retrospectively reviewed and survival was evaluated with
regard to risk factors, including the PT-Hb until June 2002. Sur-
vival was calculated using Kaplan-Meier limit methods. Risk factor
subgroups were compared with the log rank test. The PT-Hb
levels were determined within 2 weeks of conditioning chemora-
diotherapy. Results: PT-Hb levels correlated inversely with sur-
vival. The percentile 5-year survival of patients with PT-Hb levels
of 100, 101-110, 111-120, 121-130 and 130 g/L were 35, 29,
46, 62, and 57, respectively, not taking into account any other
known transplant-related risk factors. Patients with PT-Hb levels
of 110 g/L compared to 110 g/L had 5-year survival rates of
33% versus 56% (p  0.001). The effect of the PT-Hb on survival
was sustained in subgroups of patients presenting with low or
high-risk disease at the time of BMT. The overall 5-year survival
rate was 46%. By univariate analyses, the PT-Hb, the use of
unrelated donors, BMT in patients with more advanced disease
and major ABOmismatch between donor and recipient were found
to be signiﬁcant risk factors for mortality. In a multivariate model,
a low PT-Hb level was found to be an independent risk factor (p
0.001; hazard ratio, 1.19 per 10 g/L decrease; 95% CI, 1.10–1.28).
Conclusion: Pre-transplant anemia is an independent risk factor
for increased long-term mortality during alloBMT. It remains to
be determined whether decreased survival is the result of direct
effects from anemia or, alternatively, a low PT-Hb level may
represent surrogate marker for other adverse transplant-related
parameters.
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LOW DOSE TOTAL BODY IRRADIATION, FLUDARABINE AND ANTI-
THYMOCYTE GLOBULIN CONDITIONING FOR MULTIPLE MYELOMA
(MM)
Grosskreutz, C.L., Scigliano, E., Fruchtman, S.M., Luis, I.M. Mount
Sinai Medical Center, New York, NY.
Seven patients with multiple myeloma underwent non-myeloab-
lative stem cell transplant (NST) with ATG 15 mg/kg/day days -4
to -1, TBI 200 cGy on a single fraction on day -5, and ﬂudarabine
30 mg/m2/day on days -4 to -2. Immunosuppressive therapy was
oral mycophenolate mofetil 15 mg/kg every 12 hours and cyclo-
sporine 6 mg/kg every 12 hours started on day -5. Grafts were
unmanipulated PBPC mobilized with ﬁlgrastim 10 ug/kg/day and
collected on day 5. The median age of the recipients was 54 years
(range, 38-60). Three patients had 2 prior autologous stem cell
transplant (ASCT) and 3 had one prior ASCT. Three patients had
refractory MM, 2 had PR to prior therapies, 1 had relapsed disease
and 1 was in CR at the time of transplant. Three patients had
cytogenetics abnormalities: 2 had del 13q14 and 1 del q20. Three
patients had monoclonal IgG kappa, 2 IgA kappa and 2 kappa light
chains. Six patients received a full match related graft and one had
full match (10/10) unrelated donor graft. Five of seven patients
were evaluable for chimerism. Three had 90% and 2 had 80%
donor chimerism by day 30. Four patients are alive two of them in
CR with a follow up time of 307 and 951 days. One of them had
refractory disease at the time of NST. One patient is 61 days post
transplant in PR showing continued response. One patient is 93
days post transplant and has a mixed response evidenced by com-
plete disappearance of plasma cells in bone marrow and normal
IPEP but a new plasmacytoma in the skull. Three patients died; 2
from infectious complications on days 40 and 57 and one at day 19
with CNS toxicity presumed secondary to ﬂudarabine. One patient
developed pulmonary aspergillosis and CMV disease, both re-
solved with appropriate therapy. Three patients developed acute
GvHD, 2 had cutaneous grade I and 1 grade III of liver, gut and
skin (unrelated donor graft). All 3 are alive with resolution of the
GvHD.The addition of ATG to low dose TBI, ﬂudarabine NST
conditioning results in high rate of donor chimerism, preserved
graft versus myeloma effect and might help decrease the incidence
or severity of GvHD by in vivo T-cell depletion. These results
provide an alternative to reduced intensity conditioning with mel-
phalan for allogeneic transplantation in MM.
108
IMPROVING DOSING PRECISION IN BUSULFAN (BU)-BASED PREPAR-
ATIVE REGIMENS FOR HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT) USING PARMACOKINETICS DIRECTED THERAPY (PKDT)
Nance, A.G., Teresi, W.M., Vaughan, W.P., McKay, J.T., Salzman,
D.E. University of Alabama Hospital, Birmingham, AL.
Variation in po Bu absorption and metabolism in patients (Pts)
undergoing HSCT contributes to increased relapse rate and excess
toxicity. PK studies with ivBu conﬁrm minimal variation in area
under the concentrationXtime curve (AUC) in serial doses given to
individual Pts and reduction in variation in time to max dose, but
little decrease in interpatient variation. These studies suggest that
dosing to achieve a precise drug exposure based upon test dose PK
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